Start with a health concern. Understand the options, compare them, and save what matters. Open My Journal
Start My Journal
DiscoverCompareLearnHow We VerifyMy JournalStart My Journal
No. 004peptide

Retatrutide

Retatrutide is a peptide that is research only, not approved for human use in the US.

Also known as LY3437943, Reta, triple agonist

Retatrutide activates GIP, GLP-1 and glucagon receptors at once. It has drawn attention for large weight losses in Lilly's trials, and it is widely sold online as a "research peptide" ahead of any approval.

Macro close-up of empty glass sample vial openings arranged in a bright blue laboratory tray.
Research only · Not for human use
Not approved for human useNot approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. If you are considering it, a clinician can talk through approved alternatives.
Lawful options in weight

Is Retatrutide legal in the US?

Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. Investigational as of September 2026: not FDA-approved, and not eligible for compounding. The only lawful access is through Lilly's clinical trials or its pre-approval expanded access program.

As of September 23, 2026.

Key takeaways

  • Retatrutide is an experimental weight-loss drug from Eli Lilly that acts on three hormone receptors. It is not approved.
  • In the TRIUMPH-1 phase 3 trial, participants in the highest-dose group lost about 28% of body weight on average over 80 weeks, versus about 2% on placebo.
  • FDA says it cannot be used in compounding, and has sent warning letters to companies selling it as a "research" product.
  • The only lawful way to take it today is inside a clinical trial.

How does Retatrutide work?

Proposed from lab and animal studies

Retatrutide is a single molecule that switches on three receptors at once: GLP-1 and GIP, the same appetite hormones targeted by tirzepatide, plus glucagon, which may increase energy use.

Unlike most research-only peptides, it has been studied in large human trials. What is still missing is FDA review of its full safety data and an approved label.

Bright blue liquid pours from a glass flask into a row of clear laboratory test tubes under clean lab light.
Empty glass test tubes with white caps neatly arranged in a rack, pale and clinical in tone.

What does the evidence say about Retatrutide?

Emerging evidence

A published phase 2 trial showed large average weight loss; phase 3 results have been announced but full long-term safety data are still under review.

Why are clinicians and regulators cautious about Retatrutide?

Obesity specialists are watching retatrutide closely because its trial results are striking. Regulators are clear that products sold outside trials are unapproved and of unknown quality.

Summaries of published guidelines, drug labels, regulators and reviews, each attributed to its source. DiscoverMedica does not employ clinicians.

Who should avoid Retatrutide?

Especially important to avoid if

  • Anyone considering a "research" product bought online: identity, purity and sterility are unverified
  • Anyone with a personal or family history of medullary thyroid cancer or MEN 2, who were excluded from trials
  • Pregnancy or breastfeeding
  • A history of pancreatitis

What are the risks and side effects of Retatrutide?

  • Not approved for human use. Products sold online as "research chemicals" are not made to drug standards, so identity, purity, sterility and dose are unverified.
  • FDA has warned that unapproved GLP-1-type products sold online can be counterfeit, contaminated or mislabeled.
  • Trial participants reported GI side effects and increased heart rate; the full safety profile is not yet known.
  • Expect the same class concerns as other incretin drugs (pancreatitis, gallbladder disease), though its label, if approved, is not written yet.

What should you ask a clinician about Retatrutide?

  • Is there a retatrutide trial or expanded access program I might qualify for?
  • Which approved medication would give me the closest option today?

These save with the compound when you add it to My Journal, so they’re on the printout for your visit.

Where can I get Retatrutide?

Retatrutide is not approved for human use, so DiscoverMedica links to no seller.

We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.

Compare and learn

Retatrutide: questions, answered

Is retatrutide approved?

No. It is still investigational. Lilly has said it plans to submit it to FDA, but no approval exists as of September 2026.

How much weight did people lose in trials?

In TRIUMPH-1, participants in the highest-dose group lost about 28% of body weight on average over 80 weeks, versus about 2% on placebo. These are trial averages under close medical supervision.

Can I get it from a telehealth provider?

No. Retatrutide is not FDA-approved and has no lawful compounding route, so there is nothing a licensed telehealth provider can legitimately prescribe. If a site offers it, treat that as a warning sign. DiscoverMedica does not link to anyone selling it.

How can I take part in a trial?

Search ClinicalTrials.gov for retatrutide or TRIUMPH, or ask your clinician about trials near you.

What does "research use only" mean?

It means the product is not made or tested for people. FDA has sent warning letters to sellers who use that label while making health claims, and says it judges a product by how it is marketed, not by the disclaimer.

Important safety information

Retatrutide is not approved for human use in the US. Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it.

Key risks

  • Not approved for human use. Products sold online as "research chemicals" are not made to drug standards, so identity, purity, sterility and dose are unverified.
  • FDA has warned that unapproved GLP-1-type products sold online can be counterfeit, contaminated or mislabeled.
  • Trial participants reported GI side effects and increased heart rate; the full safety profile is not yet known.
  • Expect the same class concerns as other incretin drugs (pancreatitis, gallbladder disease), though its label, if approved, is not written yet.

Avoid it especially if

  • Anyone considering a "research" product bought online: identity, purity and sterility are unverified
  • Anyone with a personal or family history of medullary thyroid cancer or MEN 2, who were excluded from trials
  • Pregnancy or breastfeeding
  • A history of pancreatitis

This is not a complete list of risks. Talk to a licensed clinician or pharmacist about your own situation. If you have a severe reaction, call 911. You can report side effects to the FDA through MedWatch at 1-800-FDA-1088.

Sources

Also checked for this guide

Guide reviewed September 23, 2026.

Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.

Lawful options in the same goal

Related compounds.

Semaglutide

medication

A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.

PrescriptionStrong human evidence
24 providers

Tirzepatide

medication

A weekly GIP and GLP-1 medication approved for weight management, sleep apnea and type 2 diabetes.

PrescriptionStrong human evidence
22 providers

Liraglutide

medication

An older, daily GLP-1 injection for weight management and diabetes, now available as a generic.

PrescriptionStrong human evidence
12 providers

Metformin

medication

A cheap, decades-old diabetes pill that some people ask about for weight and healthy aging.

PrescriptionModerate human evidence
12 providers